内蒙古医学杂志
內矇古醫學雜誌
내몽고의학잡지
Inner Mongolia Medical Journal
2015年
2期
146-150
,共5页
非小细胞肺癌%核苷酸切除修复交错互补基因1%核苷酸还原酶M1%铂类%吉西他滨
非小細胞肺癌%覈苷痠切除脩複交錯互補基因1%覈苷痠還原酶M1%鉑類%吉西他濱
비소세포폐암%핵감산절제수복교착호보기인1%핵감산환원매M1%박류%길서타빈
nonsmall cell lung cancer%ERCC1%RRM1%gemcitabine%cisplatin
目的：研究探讨晚期非小细胞肺癌（nonsmall cell lung cancer ，NSCLC ）组织中核苷酸切除修复交错互补基因1（ERCC1）和核苷酸还原酶M 1（RRM 1）表达与吉西他滨／铂类化疗方案疗效的关系。方法应用免疫组织化学方法对80例晚期NSCLC穿刺或手术标本为材料进行ERCC1和RRM1蛋白表达检测。对患者化疗后的疗效与 ERCC1、RRM 1表达水平的关系进行评价。结果80例患者中，ERCC1阳性患者与阴性患者有效率分别为28．8％、71．4％，RRM1阳性患者与阴性患者化疗有效率分别为30．2％、70．4％，阳性患者与阴性患者有效率比较，差异均有统计学意义（ P均＜0．05）。ERCC1、RRM 1均阴性表达者化疗有效率明显高于阳性表达者（66．1％ vs31．8％，P＜0．05）。结论ERCC1和RRM1的表达不同可能是吉西他滨／铂类化疗方案中药物敏感性差别的重要因素，可能为临床NSCLC 患者个体化用药提供参考的依据。
目的：研究探討晚期非小細胞肺癌（nonsmall cell lung cancer ，NSCLC ）組織中覈苷痠切除脩複交錯互補基因1（ERCC1）和覈苷痠還原酶M 1（RRM 1）錶達與吉西他濱／鉑類化療方案療效的關繫。方法應用免疫組織化學方法對80例晚期NSCLC穿刺或手術標本為材料進行ERCC1和RRM1蛋白錶達檢測。對患者化療後的療效與 ERCC1、RRM 1錶達水平的關繫進行評價。結果80例患者中，ERCC1暘性患者與陰性患者有效率分彆為28．8％、71．4％，RRM1暘性患者與陰性患者化療有效率分彆為30．2％、70．4％，暘性患者與陰性患者有效率比較，差異均有統計學意義（ P均＜0．05）。ERCC1、RRM 1均陰性錶達者化療有效率明顯高于暘性錶達者（66．1％ vs31．8％，P＜0．05）。結論ERCC1和RRM1的錶達不同可能是吉西他濱／鉑類化療方案中藥物敏感性差彆的重要因素，可能為臨床NSCLC 患者箇體化用藥提供參攷的依據。
목적：연구탐토만기비소세포폐암（nonsmall cell lung cancer ，NSCLC ）조직중핵감산절제수복교착호보기인1（ERCC1）화핵감산환원매M 1（RRM 1）표체여길서타빈／박류화료방안료효적관계。방법응용면역조직화학방법대80례만기NSCLC천자혹수술표본위재료진행ERCC1화RRM1단백표체검측。대환자화료후적료효여 ERCC1、RRM 1표체수평적관계진행평개。결과80례환자중，ERCC1양성환자여음성환자유효솔분별위28．8％、71．4％，RRM1양성환자여음성환자화료유효솔분별위30．2％、70．4％，양성환자여음성환자유효솔비교，차이균유통계학의의（ P균＜0．05）。ERCC1、RRM 1균음성표체자화료유효솔명현고우양성표체자（66．1％ vs31．8％，P＜0．05）。결론ERCC1화RRM1적표체불동가능시길서타빈／박류화료방안중약물민감성차별적중요인소，가능위림상NSCLC 환자개체화용약제공삼고적의거。
Objective To investigate the expression of excision repair cross complementing gene 1 (ERCC1 ) and ribonucleotide reductase subunitM 1 (RRM1 ) in non small cell lung cancer (NSCLC) ,and study the correla-tion of ERCC1/RRM1 expression with the therapeutical effect of platinum/gemcitabine chemotherapy in pa-tients with NSCLC .Methods 8 0 patients with advanced NSCLC were enrolled in the study . Immunhisto-chemistry for paraffinem bedded tumor specimens was performed to investigate ERCC 1 and RRM 1 expression . Results In 80 patients ,The positive and negative rates of ERCC1 expression in NSCLC samples were 28 .8%and 7 1 .4% respec tively .The positive and negative rates of RRM 1 expression in NSCLC samples were 3 0 .2%and 7 0 .4% respectively ,The therapeutic effect of platinum/gemcitabine in patient with ERCC1 low expression was obviously better than that with ERCC1 high expression(P=0 .036 ) .the difference was statistically signifi-cant between that ,so is the RRM1 .Conclusion Application of gemcitabine/platinum chemotherapy treatment , the expression difference of ERCC1 and RRM1 may be an important factor of drug sensitivity difference ,it may provide reference of individualized medication for NSCLC patients .
